Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Pharmaceutical Companies
  4. Swedish Orphan Biovitrum
Thumbnail
March 09, 2022

Sanofi scores a win with long-acting haemophilia project

Interim results on bleeds look impressive, but more data are needed to gauge efanesoctocog alfa's chances against Roche's Hemlibra.

Thumbnail
December 22, 2021

Key big pharma catalysts to kick off 2022

Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.

Article image
Vantage logo
December 21, 2021

Sanofi moves further into next-gen oncology

Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.

Article image
Vantage logo
December 06, 2021

Bavarian Nordic goes it alone, for now

Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.

Article image
Vantage logo
November 01, 2021

RSVVW 2021 – Pfizer gets maternal

Positive phase 2 data with the group’s maternal RSV vaccine set up a busy 2022 for work on the infectious disease.

Article image
Vantage logo
September 01, 2021

Bavarian Nordic gets a vaccine booster

The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.

Article image
Vantage logo
July 12, 2021

Sigilon hold hurts ahead of key haemophilia meeting

After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.

Article image
Vantage logo
February 12, 2021

Novartis’s canakinumab cancer test approaches

Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?

Article image
Vantage logo
November 26, 2020

Glaxo moves up a place in the RSV treatment race

The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.

Article image
Vantage logo
November 19, 2020

Some of biopharma’s biggest assets face a solo existence

A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.

Article image
Vantage logo
October 28, 2020

Another complement factor enters the deal-making frame

Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.